NCT02446691View on ClinicalTrials.gov

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

PHASE4CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 13, 2015

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

MenACWY

Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.

Trial Locations (6)

425 707

GSK Investigational Site, Ansan-si

400 711

GSK Investigational Site, Incheon

561 712

GSK Investigational Site, Jeonju

463 707

GSK Investigational Site, Seongnam-si

110 744

GSK Investigational Site, Seoul

158 710

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02446691 - Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations | Biotech Hunter | Biotech Hunter